2018
November 18
Clinical Genomics partners with the Colorectal Cancer Alliance in the Life After Cancer Mission
November 01
Clinical Genomics and Quest Diagnostics extend collaboration to provide InSure® ONE™, a fecal immunochemical test for colorectal cancer screening programs
October 26
Clinical Genomics appoints Betsy Hanna as Chief Commercial Officer
October 16
Two new Board of Director appointments to liquid biopsy company Clinical Genomics
October 11
Clinical Genomics to Attend AAFP’s Family Medicine Experience (FMX) in New Orleans to Promote InSure® ONE for Colorectal Cancer Screening Programs
August 24
Clinical Genomics is proud to support Strides for Life and Super Bowel I
June 14
Clinical Genomics Pathology Inc. receives licensure from State of California Department of Public Health
June 01
Biotech with Liquid Biopsy for Colorectal Cancer Secures $26 Million in New Funding
May 30
Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society
May 24
Clinical Genomics Presents Clinical Utility Data for COLVERA™ at 2018 ASCO Annual Meeting
March 06
Clinical Genomics Pathology Inc. receives licensure from Florida Agency for Healthcare Administration
February 01
Pivotal study reports InSure® FIT™ offers superior sensitivity for colorectal cancer screening
January 18
Clinical Genomics appoints Tadd Lazarus, M.D., as Chief Medical Officer
November 18
Clinical Genomics partners with the Colorectal Cancer Alliance in the Life After Cancer Mission
November 01
Clinical Genomics and Quest Diagnostics extend collaboration to provide InSure® ONE™, a fecal immunochemical test for colorectal cancer screening programs
October 26
Clinical Genomics appoints Betsy Hanna as Chief Commercial Officer
October 16
Two new Board of Director appointments to liquid biopsy company Clinical Genomics
October 11
Clinical Genomics to Attend AAFP’s Family Medicine Experience (FMX) in New Orleans to Promote InSure® ONE for Colorectal Cancer Screening Programs
August 24
Clinical Genomics is proud to support Strides for Life and Super Bowel I
June 14
Clinical Genomics Pathology Inc. receives licensure from State of California Department of Public Health
June 01
Biotech with Liquid Biopsy for Colorectal Cancer Secures $26 Million in New Funding
May 30
Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society
May 24
Clinical Genomics Presents Clinical Utility Data for COLVERA™ at 2018 ASCO Annual Meeting
March 06
Clinical Genomics Pathology Inc. receives licensure from Florida Agency for Healthcare Administration
February 01
Pivotal study reports InSure® FIT™ offers superior sensitivity for colorectal cancer screening
January 18
Clinical Genomics appoints Tadd Lazarus, M.D., as Chief Medical Officer
2017
December 19
Clinical Genomics Pathology Inc. Receives Accreditation from College of American Pathologists (CAP) for Liquid Biopsy Lab
December 12
Roy Davis joins liquid biopsy company Clinical Genomics board of directors
November 30
Clinical Genomics receives CSIRO award for Entrepreneurship in Science
November 28
Clinical Genomics appoints Roger Moody as Chief Financial Officer
November 13
Clinical Genomics and Quest Diagnostics announce FDA 510(K) clearance of InSure® ONE™
October 19
Clinical Genomics Working with Leading Cancer Center to Evaluate Colvera™ in Patients with Colorectal Cancer
August 31
“Liquid biopsy” colorectal cancer blood test celebrates Eureka moment
August 24
Clinical Genomics hits a milestone in colon cancer prevention
August 21
QIAGEN and Clinical Genomics partner on liquid biopsies to monitor patients for recurrence of colorectal cancer
August 03
New “liquid biopsy” blood test for colorectal cancer set for Eureka moment
June 09
Data Presented at ASCO Annual 2017 Shows Clinical Utility of Colvera™ in Assessing and Monitoring Patients Following Surgical Resection of Colorectal Cancer
May 31
Clinical Genomics to Present Data at ASCO Supporting Clinical Utility of Colvera™ in Assessing and Monitoring Patients Following Surgical Resection of Colorectal Cancer
March 08
Clinical Genomics Announces Participation in Fortified Provider Network and MultiPlan
January 18
Clinical Genomics to Present Data at ASCO GI Supporting Clinical Utility of Colvera™ in Assessing and Monitoring Patients Following Surgical Resection of Colorectal Cancer
December 19
Clinical Genomics Pathology Inc. Receives Accreditation from College of American Pathologists (CAP) for Liquid Biopsy Lab
December 12
Roy Davis joins liquid biopsy company Clinical Genomics board of directors
November 30
Clinical Genomics receives CSIRO award for Entrepreneurship in Science
November 28
Clinical Genomics appoints Roger Moody as Chief Financial Officer
November 13
Clinical Genomics and Quest Diagnostics announce FDA 510(K) clearance of InSure® ONE™
October 19
Clinical Genomics Working with Leading Cancer Center to Evaluate Colvera™ in Patients with Colorectal Cancer
August 31
“Liquid biopsy” colorectal cancer blood test celebrates Eureka moment
August 24
Clinical Genomics hits a milestone in colon cancer prevention
August 21
QIAGEN and Clinical Genomics partner on liquid biopsies to monitor patients for recurrence of colorectal cancer
August 03
New “liquid biopsy” blood test for colorectal cancer set for Eureka moment
June 09
Data Presented at ASCO Annual 2017 Shows Clinical Utility of Colvera™ in Assessing and Monitoring Patients Following Surgical Resection of Colorectal Cancer
May 31
Clinical Genomics to Present Data at ASCO Supporting Clinical Utility of Colvera™ in Assessing and Monitoring Patients Following Surgical Resection of Colorectal Cancer
March 08
Clinical Genomics Announces Participation in Fortified Provider Network and MultiPlan
January 18
Clinical Genomics to Present Data at ASCO GI Supporting Clinical Utility of Colvera™ in Assessing and Monitoring Patients Following Surgical Resection of Colorectal Cancer
2016
December 21
Clinical Genomics Appoints Mark Boyle President, In Vitro Diagnostics
December 20
Clinical Genomics Announces the Launch of Colvera™ for Colorectal Cancer Recurrence Monitoring
November 14
Clinical Genomics Announces Appointment of Michael Dugan, M.D. as Chief Medical Officer
October 13
Clinical Genomics Strengthens its Leadership Team with Multiple Key Appointments
October 12
Data Published in Cancer Medicine Demonstrate Clinical Genomics’ Blood Test for Colorectal Cancer Recurrence is Two-Fold More Sensitive than CEA Test
September 29
Clinical Genomics Celebrates Ten Years of Innovation
June 02
Clinical Genomics Announces Implementation of UNIConnect® Precision Molecular Diagnostics Laboratory Information Management System
March 23
Clinical Genomics Announces Closing of $15 Million Series A Financing Round
March 02
Clinical Genomics and its exclusive China partner BioChain Group receive CFDA approval for InSure® FIT™ in China
January 25
Clinical Genomics Presents Data Supporting Novel 2-Gene Blood Test for Earlier Detection of Colorectal Cancer Recurrence at ASCO GI
January 21
Clinical Genomics to Present Data Supporting Utility of 2-Gene Blood Test for Colorectal Cancer Recurrence at ASCO GI
December 21
Clinical Genomics Appoints Mark Boyle President, In Vitro Diagnostics
December 20
Clinical Genomics Announces the Launch of Colvera™ for Colorectal Cancer Recurrence Monitoring
November 14
Clinical Genomics Announces Appointment of Michael Dugan, M.D. as Chief Medical Officer
October 13
Clinical Genomics Strengthens its Leadership Team with Multiple Key Appointments
October 12
Data Published in Cancer Medicine Demonstrate Clinical Genomics’ Blood Test for Colorectal Cancer Recurrence is Two-Fold More Sensitive than CEA Test
September 29
Clinical Genomics Celebrates Ten Years of Innovation
June 02
Clinical Genomics Announces Implementation of UNIConnect® Precision Molecular Diagnostics Laboratory Information Management System
March 23
Clinical Genomics Announces Closing of $15 Million Series A Financing Round
March 02
Clinical Genomics and its exclusive China partner BioChain Group receive CFDA approval for InSure® FIT™ in China
January 25
Clinical Genomics Presents Data Supporting Novel 2-Gene Blood Test for Earlier Detection of Colorectal Cancer Recurrence at ASCO GI
January 21
Clinical Genomics to Present Data Supporting Utility of 2-Gene Blood Test for Colorectal Cancer Recurrence at ASCO GI